{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:55:23Z","timestamp":1790920523871,"version":"4.1.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Systemic sclerosis (SSc) is a complex autoimmune disease marked by vasculopathy, immune dysregulation, and progressive fibrosis of the skin and internal organs. The high disease burden and impact on quality of life highlight the need for therapies that target underlying pathogenic mechanisms rather than merely treating organ-specific symptoms. Phosphodiesterases, including phosphodiesterase 4B (PDE4B), are key regulators of cellular function and inflammatory responses of several cell types central to SSc pathogenesis. Given PDE4B\u2019s broad effects, targeting it may provide benefits beyond organ-specific manifestations and improve current care. Selective PDE4B inhibition represents a novel therapeutic approach for SSc, with improved subtype selectivity compared with earlier pan-PDE4 inhibitors. Nerandomilast preferentially inhibits PDE4B (ninefold over PDE4D), potentially improving tolerability versus oral pan-PDE4 inhibitors by avoiding adverse events such as gastrointestinal intolerance. Preclinical findings in SSc-relevant mouse and cell models show that PDE4B inhibition modulates inflammatory cytokine secretion, smooth muscle cell tension, endothelial and epithelial barrier integrity, and extracellular matrix synthesis under oxidative stress; this suggests nerandomilast could attenuate immune dysregulation, fibrosis, and potentially impact vasculopathy. Two pivotal Phase III trials evaluated nerandomilast in patients with idiopathic pulmonary fibrosis (FIBRONEER\u2122-IPF; NCT05321069) and progressive pulmonary fibrosis (FIBRONEER\u2122-ILD; NCT05321082), the latter of which included patients with SSc-associated interstitial lung disease (SSc-ILD). The ongoing CONQUEST trial (NCT06195072) is investigating the efficacy and safety of various drugs, including nerandomilast, in patients with early active SSc-ILD. This perspective highlights the rationale for targeting PDE4B in SSc therapy and explores preclinical findings in SSc and clinical findings in SSc-ILD to date.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1829186","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:35:32Z","timestamp":1790919332000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Preferential phosphodiesterase inhibition as a novel strategy to modulate key pathways in systemic sclerosis"],"prefix":"10.3389","volume":"17","author":[{"given":"J\u00f6rg H. W.","family":"Distler","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University Hospital D\u00fcsseldorf, Heinrich Heine University","place":["D\u00fcsseldorf, Germany"]},{"name":"Hiller Research Center, University Hospital D\u00fcsseldorf, Heinrich Heine University","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Frech","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Immunology, Department of Internal Medicine, Vanderbilt University Medical Center, Tennessee Valley Healthcare System Veterans Affairs Medical Center","place":["Nashville, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna H.","family":"McMahan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, UTHealth Houston","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081066","article-title":"Novel therapeutic strategies in the treatment of systemic sclerosis","volume":"16","author":"Gumkowska-Sroka","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08889-8","article-title":"Current concepts on the pathogenesis of systemic sclerosis","volume":"64","author":"Truchetet","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13630","article-title":"Oxidative stress in the pathogenesis of systemic scleroderma: an overview","volume":"22","author":"Vona","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","article-title":"Update on morbidity and mortality in systemic sclerosis-related interstitial lung disease","volume":"6","author":"Volkmann","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B8","unstructured":"OFEV\u00ae (nintedanib): Prescribing information\n          \n          \n          \n          2024"},{"key":"B9","unstructured":"ACTEMRA\u00ae (tocilizumab): Prescribing information\n          \n          \n          \n          2021"},{"key":"B10","unstructured":"Ofev\u00ae (nintedanib): Summary of product characteristics\n          \n          \n          \n          2024"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.11.003","article-title":"Advancements in the treatment of interstitial lung disease in systemic sclerosis with the approval of mycophenolate mofetil","volume":"62","author":"Takada","year":"2024","journal-title":"Respir Investig"},{"key":"B12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000533","article-title":"Haematopoietic stem cell transplantation in systemic sclerosis","volume":"4","author":"Walker","year":"2018","journal-title":"RMD Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04238-4","article-title":"Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases","volume":"32","author":"D\u00fcsing","year":"2026","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004704","article-title":"Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases","volume":"10","author":"Aringer","year":"2024","journal-title":"RMD Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1407871","article-title":"PDE4 inhibitors: potential protective effects in inflammation and vascular diseases","volume":"15","author":"Fan","year":"2024","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2023-0101","article-title":"PDE4 inhibitors for disease therapy: advances and future perspective","volume":"15","author":"Du","year":"2023","journal-title":"Future Med Chem"},{"key":"B22","doi-asserted-by":"publisher","first-page":"220206","DOI":"10.1183\/16000617.0206-2022","article-title":"Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis","volume":"32","author":"Kolb","year":"2023","journal-title":"Eur Respir Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.321365","article-title":"Targeting PDE4B (phosphodiesterase-4 subtype B) for cardioprotection in acute myocardial infarction via neutrophils and microcirculation","volume":"131","author":"Wan","year":"2022","journal-title":"Circ Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449","article-title":"BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Herrmann","year":"2022","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf142.172","article-title":"The preferential PDE4B inhibitor nerandomilast (BI 1015550) exhibits antifibrotic and anti-inflammatory effects in human in vitro SSc models","volume":"64","author":"Schniertshauer","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-024-02153-9","article-title":"Nerandomilast improves bleomycin-induced systemic sclerosis-associated interstitial lung disease in mice by regulating the TGF-\u03b21 pathway","volume":"48","author":"Liu","year":"2025","journal-title":"Inflammation"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2024-0614OC","article-title":"Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast","volume":"73","author":"Reininger","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001016RR","article-title":"PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice","volume":"34","author":"McDonough","year":"2020","journal-title":"FASEB J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00845-w","article-title":"Effect of vasodilator and immunosuppressive therapy on the endothelial dysfunction in patients with systemic sclerosis","volume":"23","author":"Bhattacharjee","year":"2023","journal-title":"Clin Exp Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2174\/0115733971261932231025045400","article-title":"Cellular transdifferentiation: a crucial mechanism of fibrosis in systemic sclerosis","volume":"20","author":"Jimenez","year":"2024","journal-title":"Curr Rheumatol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3390\/jcm9092687","article-title":"The pathogenesis of systemic sclerosis: An understanding based on a common pathologic cascade across multiple organs and additional organ-specific pathologies","volume":"9","author":"Asano","year":"2020","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05499-9","article-title":"Serum IL-17 and TNF\u03b1 as prognostic biomarkers in systemic sclerosis patients: a prospective study","volume":"44","author":"Kosa\u0142ka-W\u0119giel","year":"2024","journal-title":"Rheumatol Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1515\/rjim-2015-0006","article-title":"IL-17, IL-6 and IFN-\u03b3 in systemic sclerosis patients","volume":"53","author":"Balanescu","year":"2015","journal-title":"Rom J Intern Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814287","article-title":"The pathogenesis of systemic sclerosis: the origin of fibrosis and interlink with vasculopathy and autoimmunity","volume":"24","author":"Ko","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.609653","article-title":"Mechanical and physical regulation of fibroblast-myofibroblast transition: from cellular mechanoresponse to tissue pathology","volume":"8","author":"D'Urso","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1051\/medsci\/20163202012","article-title":"Pathophysiology of systemic sclerosis","volume":"32","author":"Allanore","year":"2016","journal-title":"Med Sci (Paris)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2007.11.002","article-title":"Fibrosis in systemic sclerosis","volume":"34","author":"Varga","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"key":"B39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","article-title":"Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis","volume":"19","author":"Torres","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.5530\/jyp.20251506","article-title":"Systematizing PDE4 inhibition in psoriasis treatment: roflumilast leads the way","volume":"17","author":"Ravindran","year":"2025","journal-title":"J Young Pharmacists"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2464107","article-title":"Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study","volume":"36","author":"L\u00e9","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100639","article-title":"Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO)","volume":"30","author":"Gyldenl\u00f8ve","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"B43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: Results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for \u2265156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70153","article-title":"Orismilast, a potent and selective PDE4B\/D inhibitor, reduces protein levels of key disease driving cytokines in the skin of patients with plaque psoriasis","volume":"34","author":"Warren","year":"2025","journal-title":"Exp Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18818","article-title":"Pharmacology of orismilast, a potent and selective PDE4 inhibitor","volume":"37","author":"Silverberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2023.11.005","article-title":"Orismilast in moderate-to-severe psoriasis: efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)","volume":"90","author":"Warren","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI15506","article-title":"Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0217-3","article-title":"Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management","volume":"14","author":"Gyger","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096123","article-title":"An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis","volume":"68","author":"Denton","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000006737","article-title":"Successful treatment of infliximab in a patient with scleroderma: a case report","volume":"96","author":"Li","year":"2017","journal-title":"Medicine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-019-00119-9","article-title":"Treatment of diffuse cutaneous systemic sclerosis with biologics, small molecules and stem cell transplantation: what is the evidence to date","volume":"5","author":"Kersten","year":"2019","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"B58","article-title":"Is there a role for TNF\u03b1 antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique","volume":"29","author":"Distler","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1713221","article-title":"The immune landscape of systemic sclerosis: from pathogenic mechanisms to precision therapeutic breakthroughs","volume":"17","author":"Liu","year":"2026","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/s8qcyu","article-title":"A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to determine the effectiveness of the type I interferon receptor antibody, anifrolumab, in systemic sclerosis: DAISY study design and rationale","volume":"42","author":"Khanna","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1186\/ar4492","article-title":"Dose-escalation of human anti-interferon-\u03b1 receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study","volume":"16","author":"Goldberg","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003500","article-title":"Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study","volume":"10","author":"Barde","year":"2024","journal-title":"RMD Open"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B66","volume-title":"The preferential PDE4B inhibitor nerandomilast (BI 1015550) exhibits antifibrotic and anti-inflammatory effects in human","author":"Schniertshauer","year":"2025"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/biom11060789","article-title":"The roles of various prostaglandins in fibrosis: a review","volume":"11","author":"Li","year":"2021","journal-title":"Biomolecules"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704705","article-title":"Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts","volume":"136","author":"Inoue","year":"2002","journal-title":"Br J Pharmacol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417601","article-title":"Immune profiling of patients with systemic sclerosis through targeted proteomic analysis","volume":"24","author":"Szabo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111132","article-title":"Systemic sclerosis fibroblasts show specific alterations of interferon-gamma and tumor necrosis factor-alpha-induced modulation of interleukin 6 and chemokine ligand 2","volume":"39","author":"Antonelli","year":"2012","journal-title":"J Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.09.288","article-title":"Fibroblast subpopulations in systemic sclerosis: functional implications of individual subpopulations and correlations with clinical features","volume":"144","author":"Zhu","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1423045","article-title":"Emerging roles of non-coding RNAs in fibroblast to myofibroblast transition and fibrotic diseases","volume":"15","author":"Xing","year":"2024","journal-title":"Front Pharmacol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/s42490-019-0014-z","article-title":"A high content, phenotypic 'scar-in-a-jar' assay for rapid quantification of collagen fibrillogenesis using disease-derived pulmonary fibroblasts","volume":"1","author":"Good","year":"2019","journal-title":"BMC BioMed Eng"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/ajrccm\/aamag058","article-title":"Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial","volume":"212","author":"Oldham","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2501899","DOI":"10.1183\/13993003.01899-2025","article-title":"Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial","volume":"68","author":"Wijsenbeek","year":"2026","journal-title":"Eur Respir J"},{"key":"B79","volume-title":"Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis: subgroup analysis of the FIBRONEER-ILD trial","author":"Hoffmann-Vold","year":"2025"},{"key":"B80","unstructured":"JASCAYD\u00ae (nerandomilast tablets): Prescribing information\n          \n          \n          \n          2025"},{"key":"B81","unstructured":"JASCAYD\u00ae (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China\n          \n          \n          \n          2025"},{"key":"B82","unstructured":"JASCAYD\u00ae (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)\n          \n          \n          \n          2025"},{"key":"B83","unstructured":"JASCAYD\u00ae (nerandomilast) approved in Japan, advancing global access to a new IPF and PPF treatment\n          \n          \n          \n          2026"},{"key":"B84","unstructured":"Anvisa aprova medicamento inovador da Boehringer Ingelheim para o tratamento de doen\u00e7as fibrosantes do pulm\u00e3o\n          \n          \n          \n          2026"},{"key":"B85","unstructured":"European Commission approves JASCAYD\u00ae, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU\n          \n          \n          \n          2026"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1177\/23971983241278079","article-title":"Design of CONQUEST, a novel, randomized, placebo-controlled, phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease","volume":"10","author":"Khanna","year":"2024","journal-title":"J Scleroderma Relat Disord"},{"key":"B87","unstructured":"A study to evaluate the efficacy and safety of nerandomilast in participants with systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD). Identifier: NCT06806592"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829186\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:35:34Z","timestamp":1790919334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829186\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2026.1829186"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1829186","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1829186"}}